Cas:403485-90-5 1-(2-Methyl-3-buten-2-yl)-1H-imidazole manufacturer & supplier

Chemical Name:1-(2-Methyl-3-buten-2-yl)-1H-imidazole

CAS.NO:403485-90-5

Synonyms:N-(Dimethoxymethyl)carbanilsaeure-methylester;Carbamic acid,(dimethoxymethyl)phenyl-,methyl ester;N-(dimethylallyl)imidazole

Molecular Formula:C₈H₁₂N₂

Molecular Weight:136.19400

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:17.82000

Exact Mass:136.10000

LogP:1.80420

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like N-(Dimethoxymethyl)carbanilsaeure-methylester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N-(dimethylallyl)imidazole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Carbamic acid,(dimethoxymethyl)phenyl-,methyl ester Use and application,N-(dimethylallyl)imidazole technical grade,usp/ep/jp grade.

Related News: In a statement to Fierce Medtech, Innova said it has completed some corrective actions, while others are still underway, and that the U.S. recall was launched to reclaim tests distributed to employees, clinical studies and to customers for early evaluation. The company said it plans to seek an emergency use authorization and comply with all FDA requirements. 1-(2-Methyl-3-buten-2-yl)-1H-imidazole manufacturer In a statement to Fierce Medtech, Innova said it has completed some corrective actions, while others are still underway, and that the U.S. recall was launched to reclaim tests distributed to employees, clinical studies and to customers for early evaluation. The company said it plans to seek an emergency use authorization and comply with all FDA requirements. 1-(2-Methyl-3-buten-2-yl)-1H-imidazole supplier Lilly has pledged to address the problems, and said none of them affected drugs in the market. The FDA, which has taken no public action, did not respond to requests for comment. 1-(2-Methyl-3-buten-2-yl)-1H-imidazole vendor GlaxoSmithKline��s HIV drugs division ViiV Healthcare said on Saturday that the U.S. Food and Drug Administration declined to approve its long acting HIV injection. 1-(2-Methyl-3-buten-2-yl)-1H-imidazole factory In a statement to Fierce Medtech, Innova said it has completed some corrective actions, while others are still underway, and that the U.S. recall was launched to reclaim tests distributed to employees, clinical studies and to customers for early evaluation. The company said it plans to seek an emergency use authorization and comply with all FDA requirements.